Company Update and Introductioncontent.stockpr.com/cancergenetics/media/1a29f0e20... · •$1 M...
Transcript of Company Update and Introductioncontent.stockpr.com/cancergenetics/media/1a29f0e20... · •$1 M...
Company Update and Introduction
November 22, 2013
Panna SharmaPresident and
Chief Executive Officer
Cancer Genetics, Inc.
8:30-9:00 am Breakfast
9:00-10:30 am Presentations
> Panna Sharma: Welcome, The NGS Marketplace:
Challenges, Opportunities & Launching OncoSpire
> Dr. Chaganti: CGI’s Contribution, The Project
Review Process & The Scientific Review
Committee at OncoSpire
> Dr. Farrugia: Center for Individualized Medicine
(Mayo) & Mayo’s NGS Contributions &
Infrastructure
> Dr. Chaganti & Dr. Farrugia: Our Three Initial
NGS Panels/ Projects, The Development Process
> Panna Sharma: Market Context & Wrapup
10:30-11:00 am Q&A and Open Dialogue
Agenda and
Presenters
RSK Chaganti, PhDFounder and
Member of the Board
Cancer Genetics, Inc.
Gianrico Farrugia, MDDirector, Center for
Individualized Medicine
Mayo Clinic
• $1 M funded in 2013 to initiate Joint Venture
• Upto $5 M in additional funding based on project milestones
• Projects Have 12 to 30 month development horizon
• Core operations based in Rochester, MN and leverage Mayo facilities
• World class NGS facility
• Best in class bioinformatics
• Globally leading clinicians
• Immediately integrated into care
• Scientific leadership
• Disease focus and stewardship
• Commercial focus and management
• Capital access and investment
Source: Research and Markets: Next Generation Sequencing.
Clinical adoption is early, but accelerating…there is
a “rush” to establish and validate meaningful
content that will drive usage and change patient
outcomes
$1.1 bil. NGS
Market (2012)
$2.7 bil. NGS
Market (2017)
Exponential growth in NGS publications
14 20 33 20 38 96261
515
990
1637
2590
0
500
1000
1500
2000
2500
3000
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Number of NGS Publications
CG
I e
sti
ma
te
Based on a PubMed search, with search term “next-generation sequencing” or “NGS”
Ten years ago there were 14 NGS publications…
for 2013 it is estimated to be 2,590
• Lack a patient informed
approach, they are driven
largely by large scale
gene and literature surveys
of known or actionable
sites
• Are not specific to
oncology sub-types
• Not unique and can be
readily replicated
• Are not answering new
questions about the
diseases
Current Approaches… Our Efforts & Approach
NGS Will Evolve…From Large Scale Gene Surveying To
Informed Discovery
• Emerge from clinically informed
teams that are trying to solve
unmet and critical needs
through genetic insight
• Disease-specific, multi-
disciplinary teams that can not
be readily recreated
• Involves novel discovery and
unique algorithms and/or
bioinformatics; potentially
patentable
• Asking questions about cancer
that are unmet and challenging
Solicited clinically-informed projects with cross-functional
team support from across Mayo
► Over 4,100 Staff Physicians & Scientist
► Over 1,200,000 Patients Annually
► Across Three US Locations: Rochester, Jacksonville, Scottsdale
20+ Projects
14 Projects
6 Projects
3 Projects
World-Class
Scientific
Review
Committee
RSK Chaganti, Ph.D.
Memorial Sloan-Kettering
Snee Chair of Cell Biology Program
Cancer Genetics, Inc.
Founder & Chairman CGI
Andrea Califano, Ph.D.
Columbia University
Director, JP Sulzberger Columbia Genome Center
Associate Director, Herbert Irving Comprehensive Cancer Center
Timothy A Chan, M.D., Ph.D.
Memorial Sloan-Kettering
Associate Professor
Human Oncology and Pathogenesis Program
Raj Dahiya, Ph.D.
Univ. of California, San Francisco
Professor, Department of Urology
Associate Editor, Cancer Research
Gianrico Farrugia, M.D.
Mayo Clinic
Director, Center for Individualized Medicine
Professor of Medicine, Physiology and Biomedical Engineering
Stephen J Russell, M.D., Ph.D.
Mayo Clinic
Director, Molecular Medicine
Professor of Medicine
Curtis A Hanson, M.D.
Mayo Clinic
Laboratory Director of Cytogenetics
Previous Medical Director of Mayo Medical Laboratories
Projects in development have significant clinical value and may yield
multiple focused panels that become the standard of care in NGS based oncology management.
Informed Discovery
Multiple Myeloma
Commercial Validation
Clinical Development
Market Entry(with partners)
Lung
Cancer
Follicular Lymphoma
1.6 millionnew cases
200,000new cases
20,920new cases